Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
2020 · Journal of Thoracic Oncology · 430 citations
https://doi.org/10.1016/j.jtho.2020.11.025
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
1.1K
Citations
15
h-index
20
i10-index
Lijia Wang is an academic researcher from University of Waterloo. The author has contributed to research in topics: Respiratory viral infections research & Pediatric health and respiratory diseases & Asthma and respiratory diseases. The author has an h-index of 15, co-authored 48 publications.
ORCID: 0000-0003-4805-1731https://doi.org/10.1016/j.jtho.2020.11.025
https://doi.org/10.1186/s12967-024-05873-6
Click to start Chat